Newsfiscal.ai
AN2 Therapeutics to Present Phase 2 Trial Design for Epetraborole in Polycythemia Vera
· Published
Article summary
AN2 Therapeutics announced it will present the design of its planned Phase 2 clinical trial for epetraborole in patients with polycythemia vera at the 18th International Congress on Myeloproliferative Neoplasms.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…